Dramatic Outcomes in Prostate Cancer Study - Mayo Clinic

Author: Mayo Clinic
Published: 2009/06/20 - Updated: 2009/07/20
Topic: Prostate Cancer - Publications List

Page Content: Synopsis - Introduction - Main

Synopsis: Patients with inoperable prostate cancer now cancer free with experimental drug therapy in combination with standardized hormone treatment and radiation therapy.

Introduction

Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

Main Item

Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

The men were participating in a clinical trial of an immuno-therapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the abdominal areas.

"The goal of the study was to see if we could modestly improve upon current treatments for advanced prostate cancer," says Eugene Kwon, M.D., Mayo Clinic urologist and leader of the clinical trial. "The candidates for this study were people who didn't have a lot of other options. However, we were startled to see responses that far exceeded any of our expectations."

The patients first received a type of hormone therapy called androgen ablation, which removes testosterone and usually causes some initial reduction in tumor size. Researchers then introduced a single dose of ipilimumab, an antibody, which builds on the anti-tumor action of the hormone and causes a much larger immune response, resulting in massive death of the tumor cells. Both men experienced consistent drops in their prostate specific antigen (PSA) counts over the following weeks until both were deemed eligible for surgery. Then, during surgery, came a greater surprise.

"The tumors had shrunk dramatically," says Michael Blute, M.D., Mayo urologist, co-investigator and surgeon, who operated on both men. "I had never seen anything like this before. I had a hard time finding the cancer. At one point the pathologist (who was working during surgery) asked if we were sending him samples from the same patient."

One patient underwent radiation therapy after surgery; both have resumed their regular lives. Further research is being planned to understand more about the mechanisms of the antibody and how best to use the approach in practice. The researchers, however, note the significance of their findings.

"This is one of the holy grails of prostate cancer research," says Dr. Kwon. "We've been looking for this for years."

The research was supported by the Department of Defense, The Richard M. Schulze Family Foundation, the Mayo Clinic Cancer Center and the Mayo Clinic Center for Translational Science Activities. Medarex, Inc. provided the study drug free of charge and supported safety monitoring during the protocol.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year.

Explore Similar Topics

- This article outlines the Prostate Imaging Reporting and Data System (PI-RADS), a critical tool for evaluating prostate cancer risk.

- This chart illustrates the different Gleason scores, their associated cancer aggressiveness, metastasis risk, and treatment considerations.

Citing and References

Founded in 2004, Disabled World (DW) is a leading resource on disabilities, assistive technologies, and accessibility, supporting the disability community. Learn more on our About Us page.

Cite This Page: Mayo Clinic. (2009, June 20 - Last revised: 2009, July 20). Dramatic Outcomes in Prostate Cancer Study - Mayo Clinic. Disabled World (DW). Retrieved March 21, 2025 from www.disabled-world.com/health/cancer/prostate/prostate-cancer-therapy.php

Permalink: <a href="https://www.disabled-world.com/health/cancer/prostate/prostate-cancer-therapy.php">Dramatic Outcomes in Prostate Cancer Study - Mayo Clinic</a>: Patients with inoperable prostate cancer now cancer free with experimental drug therapy in combination with standardized hormone treatment and radiation therapy.

While we strive to provide accurate and up-to-date information, it's important to note that our content is for general informational purposes only. We always recommend consulting qualified healthcare professionals for personalized medical advice. Any 3rd party offering or advertising does not constitute an endorsement.